Downloadable_Slides

More documents

Recommendations

Info

Brexpiprazole: Clinical Trial • Rationale – D2 partial agonist: selective impact on dopamine system • Subjects: 636 subjects with schizophrenia • Design: 6-week, randomized, doubleblind, placebo-controlled trial • Treatment: 0.25 mg, 2 mg, 4 mg dosing • Outcomes: – Placebo vs 2 mg dose: total P=.0006, positive P=.003, and negative symptoms (P=.0007) – Placebo vs 4 mg dose total P
Paliperidone Palmitate versus Placebo for Relapse Prevention • N=506, Study compared once/3-mo formulation) versus placebo • First time to relapse significantly favored paliperidone palmitate versus placebo (HR=3.45; 95% CI, P
Page 1 and 2: Across the Spectrum: Managing First
Page 3 and 4: Diana O. Perkins, MD, MPH Professor
Page 5 and 6: Outline • Achieving Appropriate a
Page 7 and 8: When to Diagnose? Progressive Stage
Page 9 and 10: When to Diagnose? Progressive Stage
Page 11 and 12: How to Diagnose? Domains of Psychos
Page 13 and 14: Treatment of First-episode Schizoph
Page 15 and 16: Stage-based Interventions Early Rec
Page 17 and 18: N-Acetyl Cysteine: Clinical Trial
Page 19 and 20: L-Theanine: Clinical Trial • Rati
Page 21: Cariprazine: Clinical Trial • Rat
Page 25 and 26: Meta-analysis: Relapse Rates First
Page 27 and 28: Are Some Patients Harmed by Antipsy
Page 29 and 30: Do Antipsychotics Contribute to Gra
Page 31 and 32: Outline • Adherence in Schizophre
Page 33 and 34: Clinical Consequences of Nonadheren
Page 35 and 36: Suicide Attempts Increase When Ther
Page 37 and 38: Unfortunately, We Overestimate Adhe
Page 39 and 40: Reverberations from Adverse Effects
Page 41 and 42: Long-acting Injectable Antipsychoti
Page 43 and 44: Impact of Collaborative Care • Re
Page 45 and 46: Choosing an Antipsychotic: Switch o

Downloadable_Slides

Create successful ePaper yourself

Delete template?

Save as template?